Down-Regulation of Thiamine Transporter THTR2 Gene Expression in Breast Cancer and Its Association With Resistance to Apoptosis

Shuqian Liu,1 Hui Huang,1 Xin Lu,1 Miroslaw Golinski,2 Sebastien Comesse,3 David Watt,2 Robert B. Grossman,3 and Jeffrey A. Moscow1

Departments of 1Pediatrics, 2Biochemistry, and 3Chemistry, University of Kentucky, Lexington, KY

Abstract
The recent molecular identification of two thiamine transporters, SLC19A2 (THTR1) and SLC19A3 (THTR2), has provided the opportunity to study thiamine transporter gene expression in human malignancies. We compared RNA levels of both THTR1 and THTR2 in a panel of human breast tumors and corresponding normal tissues. THTR2 RNA levels were down-regulated in breast cancer to 14% of the level found in corresponding normal tissues, while THTR1 levels were unchanged. Both thiamine transport genes were cloned and expressed in a breast cancer cell line to examine the impact of reconstituted thiamine transport gene expression on drug and radiation sensitivity and on resistance to apoptosis. THTR2-transfected breast cancer cells showed a 2.5-fold increase in specific THTR2 activity and a 3-fold increase in cytotoxicity against a bromoacetyl ester derivative of thiamine. Surprisingly, these cells also showed a 3-fold increase in sensitivity to doxorubicin and an increase in sensitivity to ionizing radiation, but no change in sensitivity to methotrexate or paclitaxel. TUNEL assays demonstrate an increase in apoptosis in THTR2-transfected cells exposed to doxorubicin and radiation, and Western blot analysis suggests that apoptosis associated with these cytotoxic stresses is mediated at least in part by a caspase-3-dependent pathway. Therefore, thiamine transporter THTR2 gene expression is down-regulated in breast cancer, which may contribute to resistance to apoptosis in these tumors.

Introduction
Thiamine, like folate and other essential nutrients, uses specific carrier mechanisms for transport into cells. However, unlike folate, the amount of thiamine stored in the body is usually very small. When ingested in excess of the body’s needs, this water-soluble vitamin is readily excreted in the urine, and therefore it must be continually supplied in the diet. Thiamine deficiency is most often associated with severe malnutrition, alcoholism, and fad diets (1), and clinically results in beriberi and Wernicke-Korsakoff syndromes (2).

The gene for a thiamine transport protein, THTR1, was isolated by gene mapping strategies which identified it as the cause of the thiamine-responsive megaloblastic anemia syndrome (TRMA), an autosomal-recessive disorder of megaloblastic anemia, diabetes mellitus, and sensorineural deafness (3–5). THTR1 has been shown to carry mutations in affected individuals and to encode a high-affinity thiamine transporter (3–6).

THTR1 is a member of the SLC19 family of vitamin transporters (SLC19A2), which includes the reduced folate carrier RFC1 (SLC19A1). Recently, another member of this family of genes, SLC19A3, was identified (7) and characterized as a thiamine transporter (8). To determine the potential role of thiamine transport in cancer therapy, we measured the level of expression of both thiamine transporters in a panel of human tumors and corresponding normal tissues. The down-regulation of THTR2 in breast cancer led us to investigate the potential role of thiamine transporter gene expression in the development of these tumors.

Results
THTR1 and THTR2 Expression in a Tissue Array Panel
We originally hypothesized that increased tumor cell metabolic requirements would lead to an increase in expression of thiamine transporter gene expression in tumors compared to corresponding normal tissues. Initial preliminary data had demonstrated an increase in thiamine transporter gene expression in two of six melanoma specimens (data not shown). Therefore, a cDNA microarray of 50 breast tumors and corresponding normal tissues was probing for THTR1, THTR2, and ubiquitin as a control (Fig. 1). Boxes around three specimens indicate two tumor specimens from the same individual, with the corresponding single specimen of normal tissue. The signal strength for each specimen was quantitated for each probe using a phosphorimager software, and the THTR1 and THTR2 values were normalized with the strength of the ubiquitin signal for each specimen. By this quantitative analysis, average THTR1 levels were unchanged in the 50 specimens, with the average THTR1 signal in tumors averaging 101% of the control tissue. However, the THTR2 levels averaged 14% of control levels, or an ~7-fold decrease in tumor levels versus corresponding normal tissues.
open reading frames of transporter gene expression in breast cancer, we cloned the Transfected Cells Functional Characterization of THTR1- and THTR2- T47-D) all had four cell lines we looked at (MCF-7, NCI/ADR, MDA231, and levels 2-fold higher than the mean. In contrast, the other THTR2 cancer cell lines, and the breast cancer cell line BT549 showed line HS578T had RNA levels 4-fold higher than the mean of 50 cell lines. There was much more variation in breast cancer cell lines, and did not vary markedly from the mean of 50 cell lines. The cells were selected for resistance to hygromycin, and individual clones were selected by limiting dilution for further study. As shown in Fig. 3, MTXKZ R75 cells transfected with the cDNAs for THTR1 and THTR2 both showed an increase in initial thiamine uptake relative to the control cell line. THTR2-transfected cells accumulated thiamine more rapidly than THTR1-transfected cells. The linear range of initial uptake appeared to be ~1 min. The THTR2 transgene increased the \( F_{\text{max}} \) for thiamine 2.5-fold (2 versus 5 pmol/min/mg protein in the control cells versus THTR2-transfected cells, respectively).

Because RFC1 (SLC19A1), THTR1 (SLC19A2), and THTR2 (SLC19A3) share significant peptide homology, we determined whether the two transporters shared common substrates. We could detect no incremental increase in thiamine uptake in RFC1-transfected cells compared to controls (data not shown), consistent with data previously reported by Zhao et al. (9, 10). We also could not find any evidence that there was any functional cooperation between RFC1 and THTR1 in the uptake of thiamine in cells transduced with both genes. Similarly, MTXK ZR75 cells transfected with THTR1 or THTR2 showed no significant incremental increase in the rate of initial uptake of folic acid, folinic acid, or methotrexate (data not shown), also consistent with the findings of Rajgopal et al. (8).

**Increased THTR2 Expression and Cytotoxicity of a Thiamine Analogue**

To potentially target thiamine transport for cancer therapy, we constructed several thiamine analogues. One of these drugs, a bromoacetyl derivative of thiamine (Fig. 4A), inhibited thiamine uptake (40 \( \mu \text{M} \)) to 25% of control values when present in 1000-fold excess. We therefore examined the cytotoxicity of this thiamine analogue in THTR2-transfected cells. As shown in Fig. 4B, the 2.5-fold increase in \( F_{\text{max}} \) for thiamine in these cells correlated with a 3-fold increase in the sensitivity of the transfected cells for the bromoacetyl ester derivative of thiamine. To determine whether the increase in cytotoxicity of bromoacetylthiamine in THTR2-transfected cells was due to increased activation of apoptotic pathways, we examined apoptosis by TUNEL assay (Fig. 4C) and found that the increase in bromoacetylthiamine cytotoxicity in THTR2-transfected cells correlated with an increased percentage of TUNEL-positive cells after exposure to the drug. These studies further demonstrate the presence of increased thiamine uptake activity in the THTR2-transfected MTXK ZR75 cells and the feasibility of targeting thiamine transport and thiamine-dependent pathways for cancer therapy.

**Thiamine Transport and Resistance to Chemotherapy**

We investigated the possibility that down-regulation of thiamine transport in breast cancer might play a role in oncogenesis through increased resistance to apoptosis. First, we examined cytotoxicity of three standard agents used in breast cancer treatment, paclitaxel, methotrexate, and doxorubicin, in THTR2-transfected cell lines. As can be seen in Fig. 5, there was no difference among the cell lines in activity in the THTR2-transfected MTXK ZR75 cells and the feasibility of targeting thiamine transport and thiamine-dependent pathways for cancer therapy.
lines to doxorubicin (Fig. 6A). Because there is no obvious interaction between doxorubicin and thiamine transport, we examined whether the increased sensitivity to doxorubicin in thiamine-transfected cells was associated with an increase in apoptosis after doxorubicin exposure. As shown in Fig. 6B, there was an increase in the number of cells undergoing apoptosis among cells transfected with THTR2 compared with controls at increasing concentrations of doxorubicin, suggesting that increased sensitivity to doxorubicin was associated with increased sensitivity to doxorubicin-induced apoptosis.

**Increased THTR2 Expression and Radiation Sensitivity**

We also examined whether THTR2 gene expression altered cellular sensitivity to radiation and to radiation-induced apoptosis. As shown in Fig. 7A, THTR2-transfected cells were more sensitive to ionizing irradiation than control cells. For the control cells, the SF2 was 0.35 and the D0 was 128.8 cGy. For the THTR2-transfected cells, the SF2 was 0.12 and the D0 was 81 cGy. Once again, this increase in sensitivity was associated with an increased number of cells undergoing apoptosis (Fig. 7B), suggesting that increased THTR2 expression increased the propensity of cells to undergo programmed cell death under certain conditions.

**Western Blot Analysis**

To begin to determine apoptosis pathways affected by THTR2 activity, we analyzed protein expression in THTR2-transfected cells and control cells (transfected with the empty pREP4 expression vector alone) after exposure to doxorubicin (Fig. 8A) and radiation (Fig. 8B). The results shown are representative of two independent experiments. Both vector- and THTR2-transfected cells showed induction of p53 protein at 6 h of doxorubicin treatment. No changes were observed in bcl-2 kinetics before and after treatment in both transfected cells. Interestingly, a significant decrease in the inactive form of caspase-3 was observed in THTR2-transfected cells but not in the vector-transfected cells in response to both doxorubicin and radiation, suggesting that there is an induction of cell death programs at the molecular level in THTR2-transfected cells but not in vector-transfected cells in response to these cytotoxic stresses.

**Discussion**

These studies demonstrate that THTR2 mRNA levels are down-regulated in breast cancer and suggest that this down-regulation may be associated with the development of increased resistance to apoptosis in these tumors. Furthermore, the increase in sensitivity of THTR2-transfected cells to doxorubicin and ionizing radiation, but not to paclitaxel or methotrexate, also suggests an interaction between THTR2 and the mechanisms of apoptosis. It should be noted, however, that many mechanisms in addition to dysregulation of apoptosis may result in resistance to radiation and doxorubicin, and changes in thiamine metabolism may affect multiple intracellular pathways.

The association of certain vitamin deficiencies and cancer is well known, and usually associated with environmental factors under conditions that affect all tissues. In particular, one study has drawn association between thiamine status and breast cancer (11). In addition, cell- or tissue-specific vitamin deficiencies have been associated with increased cancer risk. The pathogenesis of acute promyelocytic leukemia involves the characteristic translocation and super-repression of the retinoic acid α receptor, making these cells functionally vitamin A-deficient and unable to undergo terminal differentiation (12).
the case of folic acid, epidemiologic studies have established that the high-functioning allelic variant of the methylene-tetrahydrofolate reductase (MTHFR) gene, which shunts intracellular folate away from DNA synthesis pathways, is associated with an increased risk of acute leukemia, breast cancer, and colon cancer (13, 14).

Severe thiamine deficiencies result in tissue damage and an increase in apoptosis (15, 16), and THTR1 mutations in cells lacking other saturable route of thiamine uptake also result in severe thiamine deficiency and apoptotic cell death (16). However, the natural protective mechanisms of cells to the stress of mild thiamine deficiency, by decreasing the rate of cell turnover (17), may also set the stage for further cellular changes in a multi-step model of oncogenesis.

The analysis of the cytotoxic effects of a bromoacetyl ester analogue of thiamine demonstrates that increased expression of the thiamine transporter can make cells more sensitive to thiamine analogue compounds. Presumably, this compound acts as an alkylating agent, although it may also be an inhibitor of thiamine-dependent pathways. Because thiamine utilization is increased in tumor cells (18) and, like folate, thiamine supplementation increases tumor cell proliferation (19, 20), anti-thiamine drugs may prove to be useful in cancer therapy. However, the clinical utility of thiamine analogue compounds remains to be determined.

Perhaps most surprising is the effect of THTR2 expression on toxicity of ionizing radiation. Ruth and Roninson (21) reported that the MDR1 gene, which belongs to a different class of drug resistance genes, is upregulated by thiamine deficiency. This upregulation may explain the increased sensitivity of thiamine-deficient cells to ionizing radiation.

FIGURE 3. A. PCR reactions demonstrating presence of THTR1 and THTR2 transgenes in MTX<sup>R</sup> ZR75 cells transfected with the thiamine transporter expression vectors. B. Thiamine uptake in THTR1- and THTR2-transfected MTX<sup>R</sup> ZR75 cells. Cells were exposed to transport medium containing 20 nmol thiamine for the times indicated. C. Specific thiamine uptake attributable to the transfected thiamine transporter gene in the transfected cell lines.
of membrane transporters, inhibited radiation-induced apoptosis, but did not change the overall sensitivity of cells to radiation. Johnstone et al. (22) also demonstrated increased resistance of cells expressing \textit{MDR1} to UV irradiation, and further demonstrated a more general resistance to caspase-dependent mechanisms of cell death. Our studies with \textit{THTR2} demonstrate the opposite effect, in which increased expression of a transporter gene results in increased sensitivity to radiation. Western blot studies suggest that \textit{THTR2} expression influences the activity of the caspase-3-dependent pathway in response to cytotoxic stresses of radiation and doxorubicin exposure. Future studies will define how \textit{THTR2} interacts with caspase-dependent pathways and whether its effect on cellular resistance results as well from other determinants of cellular response to cytotoxic stress.

In addition, it is unclear whether this biological activity is caused by the transporter itself or its substrates. Once inside the cell, thiamine quickly becomes phosphorylated to thiamine PP, a key cofactor in several critical cellular pathways, including the key respiratory reactions involving the oxidation of pyruvate to acetyl CoA and \( \alpha \)-ketoglutarate to succinyl CoA, both of which reduce NAD to NADH, along with the synthesis of glyceraldehyde-3-phosphate in the pentose phosphate pathway and generation of NADPH (23). Thus, a potential role for thiamine as a radiation sensitizer is not easily seen, as it serves to enhance the reducing environment in cells, which should in turn enhance rather than inhibit recovery from oxidative stress (24, 25). However, studies of vitamin deprivation in the mouse hybridoma cell line TB/C3 revealed that thiamine deprivation improved cell viability and reduced apoptosis, suggesting that thiamine deprivation may induce a cellular stress response that may be protective (17). Further studies will determine the role of thiamine and thiamine antagonists, such as oxythiamine, on cellular sensitivity to doxorubicin and ionizing radiation.

![Structure of compound I-41](image1)

**FIGURE 4.** A. Structure of compound I-41, a bromoacetyl ester derivative of thiamine as described in “Materials and Methods.” B. Cytotoxicity assay of I-41 in MTX\(^{16}\) ZR75 cells transfected with either SLC19A3 (\textit{THTR2}) or empty vector (pREP4) control. The graph shows the results ± range of three independent experiments performed in triplicate. C. TUNEL assay of \textit{THTR2}-transfected cells versus control cells at different concentrations of bromoacetylthiamine, demonstrating increased apoptosis associated with increased cytotoxicity. The results are the average ± range of two independent determinations. At 2.5 \( \mu \)M, \( P = 0.04 \), and at 5 \( \mu \)M, \( P = 0.03 \).

![Cytotoxicity assays](image2)

**FIGURE 5.** Cytotoxicity assays of \textit{THTR2}-transfected MTX\(^{16}\) ZR75 cells and control cells against methotrexate (A) and paclitaxel (B).
Materials and Methods

Human Tissue cDNA Array

A filter array containing normalized cDNA from 50 breast cancers and corresponding normal tissues (Cancer Profiling Array, Clontech, Palo Alto, CA) was probed in succession with 32P-labeled cDNA probes for THTR1, THTR2, and ubiquitin (control) according to the methods recommended by the manufacturer. The cDNA samples were generated using SMART (Switch Mechanism At the 5' end of RNA Transcript) technology and represent the entire mRNA population from its original sample according to the manufacturer (wwwbdbiosciences.com). Of the 50 breast cancer samples, 33 carried the diagnosis of infiltrating ductal carcinoma, 10 were diagnosed as lobular carcinoma, and the remaining 7 breast tumors were assigned miscellaneous diagnoses. The precise histological description of each sample can be downloaded from the manufacturer’s website, www.clontech.com/techinfo/manuals/index.shtml#C.

THTR1 and THTR2 cDNA probes were amplified by PCR using pREP4-THTR1 and pREP4-THTR2 plasmid DNA as a template, respectively. The PCR was performed with a 30-ng template DNA in a final volume of 50 μl and 0.3 μM of each specific primer. (For THTR1: THTR1-F 5'-CTTCTTTCACCACATTTCTTAC-3' and THTR1-B 5'-GCTTCTCAATTTCTATACAC-3'. For THTR2: THTR2-F 5'-AGGTCTGTTGCTGCTGCAATCTC-3' and THTR2-B 5'-ATAGCCACATAGCAGCCAGAT-3'.) The reaction was carried out with 0.5 μl of Taq DNA polymerase (Gibco, Rockville, MD) in a thermal cycler programmed as follows: initial step for denaturation of DNA fragments, 5 min at 94°C; 40 cycles, 30 s at 94°C for denaturation; 30 s at 62°C for annealing; 30 s at 72°C for polymerization, followed by the final elongation step, 5 min at 72°C. The PCR products were purified from agarose gel using QIAquick gel extraction kit (Qiagen, Chatsworth, CA) and labeled with [32P]dCTP using the Random Primer DNA Labeling System (Promega, Madison, WI). Image acquisition and densitometry were performed using a phosphorimager.

Expression of THTR1 and THTR2 in Breast Cancer Cell Lines

Quantitative RT-PCR for measuring RNA levels was performed by using a Roche LightCycler, which uses real-time fluorescence detection for quantitative measurement of PCR products. Total RNA isolated from 50 human cancer cell lines from the NCI Drug Screen panel of cell lines was provided by the Developmental Therapeutics Program, NCI, as we have previously described (26) and includes six leukemia, five lung, seven colon, five central nervous system, six ovarian, six renal, two prostate, and seven breast cancer cell lines. All primers

FIGURE 6. A. Cytotoxicity assays of THTR2-transfected MTX R ZR75 cells and control cells against doxorubicin. B. TUNEL assay of the same cells exposed to increasing concentrations of doxorubicin. At 250 nm, control versus THTR2, n = 3, P < 0.01; at 500 nm, n = 3, P = 0.01; at 750 nm, n = 3, P = 0.02.

FIGURE 7. A. Colony forming assay of cytotoxicity of ionizing radiation in THTR2-transfected MTX R ZR75 cells and control cells. B. TUNEL assay of radiation-induced apoptosis in THTR2-transfected MTX R ZR75 cells. At 5 Gy, control versus THTR2, n = 3, P = 0.02; at 10 Gy, n = 5, P = 0.04.
**Cloning and Expressing THTR1 and THTR2**

The characteristics of THTR1 and THTR2 were defined in the background of MTXRXZ75 cells, because these cells have no detectable specific RFC activity (27, 28) which can transport thiamine monophosphate and thiamine PP_i (9, 10). First, the THTR1 cDNA was cloned by RT-PCR using skeletal muscle RNA as a template, with primers which span the putative open reading frame: THTR1- U1 5'-CAGTTGGCGGAGGAGGA-GAGGAGG-3' and at the 3' end THTR1-L2 5'-AAGGTATTAGTCAAGTGCTGCTG-3'. For THTR2, the cDNA was cloned by RT-PCR using placenta RNA as a template, with the primers which span the putative open reading frame. The primers used were: THTR2- U1 5'-GGG GTA CTC AGT GAG CGA TTT GGT GAA CAG AC-3' and THTR2-L2 5'-CCG CTC GAG TAT GCC ACC CAT CTC AAA ATC TTT-3'. Unique restriction enzyme sites for directional cloning into the multiple cloning site of the expression vector pREP4 were added to the 5' ends of these primers. MTXRXZ75 cells transfected with pREP4/THTR1 and pREP4/THTR2 and pREP4 alone were selected in hygromycin. The presence of the transgene in the surviving clones was determined by PCR. THTR1 and THTR2 cDNA were isolated from transfected cells using QIAprep spin plasmid kit (Qiagen). The PCR was performed with a 30-ng template DNA in a final volume of 50 μl and 0.3 μl of each specific primer. Each PCR reaction contained a 5' vector-specific primer. For pREP4 reaction: pREP4A 5'-TTAGGAAGGCCAACAGACAG-3' and pREP4B 5'-TTAAAACCTCCCCACCTCC-3'. For THTR1 vector: pREP4F 5'-GGAGGGGAAATGTAGTCTT-3' and THTR1-B2 5'-CAGGTTAGGAAATGTGTG-3'. For THTR2 vector: pREP4F 5'-GGAGGGGAAATGTAGTCTT-3' and THTR2-B2 5'-CAGGTTAGGAAATGTGTG-3'. The reaction was carried out with 0.5 μl of Taq DNA polymerase (Gibco) in a thermal cycler programmed as follows: initial step for denaturation of DNA fragments, 5 min at 94°C; 35 cycles, 30 s at 94°C for denaturation; 45 s at 64°C for annealing; 45 s at 72°C for polymerization, followed by the final elongation step, 5 min at 72°C.

**Kinetic Studies**

Thiamine uptake studies were performed in a manner similar to previous studies of MTX uptake (29). [3H]-labeled thiamine was obtained from American Radiolabeled Chemicals (St. Louis, MO) and its purity was assayed by the manufacturer. For drug uptake studies, cells were plated at a density of 1 × 10^5 in six-well Linbro dishes in medium containing 10% FBS. After 48–72 h of growth, cells were washed three times in transport medium (125 mM NaCl, 4.8 mM KCl, 5.6 mM d-glucose, 1.2 mM CaCl_2, 1.2 mM KH_2PO_4, 1.2 mM MgSO_4, and 25 mM HEPES, pH 7.4) without [3H]-labeled thiamine and then exposed to 20 nM [3H]-labeled thiamine in transport medium. At specified intervals, the transport medium was aspirated and the plates immersed in three successive washes of ice-cold 1× Dulbecco’s PBS containing Mg_2+ and Ca_2+ (D-PBS). The cells were then solubilized by overnight incubation in 0.2 N NaOH, neutralized with 0.2 N HCl, and the radioactivity was determined by liquid scintillation counting.
scintillation counting as previously described (30). Protein concentrations were determined by Bradford assay according to the manufacturer's instructions (Bio-Rad, Hercules, CA) using a spectrophotometer (Beckman, Fullerton, CA). Non-specific binding of drug was determined by exposure of cells to transport medium for less than 5 s, and was subtracted from measured values to indicate specific uptake.

Cytotoxicity Assays

A chemically reactive bromoacetyl ester derivative of thiamine was prepared by the straightforward reaction of acyl chlorides of the organic acids with thiamine. For cytotoxicity studies, cells transfected with the expression vector containing the THTR2 cDNA were plated in triplicate in 96-well microtiter plates in medium containing 5% FBS at densities of ~1000 cells/well. The control cell line was transfected with an empty expression vector. After 24 h, serial dilutions of drugs were added to the cells. After 6 days, the cells were fixed in 10% tricarboxylic acid, rinsed with water, and dried. The cells were then be stained with sulforhodamine in 1% acetic acid, washed with PBS, and then be stained with sulforhodamine in 1% acetic acid, washed with PBS again, and dried as previously described (29, 30). The stained cells were solubilized in 1 m Tris base (pH 10.5) and the absorbance at 570 nm determined on a microplate reader. The IC_{50} value was calculated from the dose-response curve as the concentration of drug that produced a 50% decrease in the mean absorbance compared to the untreated wells and reported as the average of at least three independent determinations performed in triplicate.

Ionizing Radiation

All experiments were irradiated using a 100-kV industrial X-ray machine (Phillips, Netherlands) at room temperature. The dose rate with a 2 mm Al plus 1 mm Be filter was ~2.64 Gy/min at a focus-surface distance of 10 cm. For colony forming assays, cells were seeded in T25 flasks at two different concentrations in quadruplicate sets for each radiation dose. Cells were left untreated or exposed to 1–6 Gy dose of radiation. After incubation for 15–20 days, colonies of at least 50 cells were scored as surviving cells. The results were plotted using X-Y log scatter (Delta Graph 4.0) and the formula of the single-event killing) and SF2 (the survival fraction of a single-cell dose of 2 Gy) as described by Chendil et al. (31).

Quantification of Apoptosis

Apoptotic cells were quantified by the terminal deoxynucleotidyl transferase-mediated nick end-labeling (TUNEL) assay using the ApopTag peroxidase in situ apoptosis detection kit (Intergen Company, Purchase, NY). In this assay, the fragmented DNA in individual cells was end-labeled using digoxigenin-labeled nucleotides at strand breaks with terminal deoxynucleotidyl transferase. Procedures were followed according to the instruction of the kit. Briefly, cells were plated in chamber slides and followed by treatment with radiation or doxorubicin (Sigma, St. Louis, MO). After incubation for 48 h at 37°C, the cells were fixed in 1% paraformaldehyde in PBS, pH 7.4. The DNA was tailed with digoxigenin-dNTP and conjugated with an anti-digoxigenin peroxidase. The cells were stained with peroxidase and methyl green. For quantitation, ~1000 cells were counted using light microscopy in each experiment, and four experiments were performed. Statistical difference between the means was analyzed with a Student t test.

Western Blot Analysis

Cells were treated with 200 nM doxorubicin or 10 Gy radiation, and harvested 0, 6, 12, 24, and 48 h after treatment. Cell pellets were resuspended in M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL). Lysed cells were centrifuged to remove cellular debris. Protein (30 μg) from each cellular lysate was size fractionated on 10% or 12.5% precast SDS-polyacrylamide gels (Bio-Rad) and electroblotted onto nitrocellulose membranes. The membrane was blocked with 5% milk in Tris-buffered saline [10 mM Tris (pH 8.0), 0.01% Tween 20] and probed with specific primary antibodies. Antibodies against bcl2, p53, and β-actin were purchased from Sigma, and antibody against caspase-3 was purchased from BD Biosciences (San Diego, CA). The membrane was washed with Tris-buffered saline and then incubated with anti-mouse IgG peroxidase conjugate (Sigma), washed with Tris-buffered saline again, and developed using a chemiluminescence detection kit according to the manufacturer's instructions (ECL-plus kit, Amersham-Pharmacia, Arlington Heights, IL). Each experiment was performed at least twice.

Acknowledgment

We gratefully acknowledge Dr. Mansoor Ahmed for his help in conducting studies of radiation exposure and his guidance in performing TUNEL assays.

References


Molecular Cancer Research

Down-Regulation of Thiamine Transporter THTR2 Gene Expression in Breast Cancer and Its Association With Resistance to Apoptosis

Shuqian Liu, Hui Huang, Xin Lu, et al.


Updated version
Access the most recent version of this article at:
http://mcr.aacrjournals.org/content/1/9/665

Cited articles
This article cites 27 articles, 9 of which you can access for free at:
http://mcr.aacrjournals.org/content/1/9/665.full.html#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/1/9/665.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.